The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Multiple myeloma highlights at ASH 2017
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple myeloma (MM) data. In this interesting interview, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, speaking from the meeting, discusses the highlights for MM. With an emphasis on data from the UK, Prof. Jackson highlights the results of specific trials, including Myeloma XI (NCT01554852), and the inclusion of patients with a poorer performance status in these trials.
